NCT01388257
Unknown
Not Applicable
A National, Multicenter, Randomized Open-Label Study of Proctological Surgery Efficacy on Anoperineal Fistulas Healing in Crohn's Disease Patients Treated With Adalimumab. (Official French Title: "Étude Nationale, Multicentrique, randomisée et en Ouvert de l'efficacité de la Chirurgie Proctologique Sur la Cicatrisation Des Fistules anopérinéales de la Maladie de Crohn Chez Des Patients traités Par Adalimumab")
French Society of Coloproctology15 sites in 1 country180 target enrollmentOctober 2011
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Crohn Disease
- Sponsor
- French Society of Coloproctology
- Enrollment
- 180
- Locations
- 15
- Primary Endpoint
- Percentage of patients having a clinical healing of their anoperineal fistulas in Crohn disease
- Last Updated
- 13 years ago
Overview
Brief Summary
The purpose of this study is to demonstrate, in patients treated with adalimumab, the efficacy of proctological surgery in anoperineal fistula healing after the removal of seton drain.
Investigators
Eligibility Criteria
Inclusion Criteria
- •male or female 18 years or older,
- •women of childbearing age who use an effective contraception method or women incapable of becoming pregnant \[(i.e. postmenopausal women for 1 year or surgically sterile (hysterectomy and/or bilateral oophorectomy)\],
- •Patient with fistulizing anoperineal Crohn's disease. Anoperineal fistulas can be associated with ileal, colic or rectal lesions,
- •Patient with at least 1 anoperineal fistula drained with a seton for more than 1 month,
- •Patient treated with adalimumab for more than 1 month,
- •Patient who agrees to undergo surgery for its drained fistula(s),
- •Patient with immunosuppressive therapy (azathioprine, 6-mercaptopurine ou methotrexate) stable for at least 3 months or patients without immunosuppressive therapy,
- •Patient who gave signed written informed consent after having received verbal explanation and written information related to the trial.
Exclusion Criteria
- •Pregnant or breastfeeding women,
- •Patient having a perineal abscess,
- •Patient with a high anovaginal fistula that cannot be treated, according to the investigator ,with fistulotomy, gluing, biodegradable plug or advancement flap,
- •Patient treated with a daily dose of corticosteroids of more than 20 mg (a dose of more than 20 mg daily will be authorized during the study),
- •Contraindication to proctological surgery on the drained fistula(s),
- •Patient presenting with somatic or psychic signs or symptoms that are not compatible with his/her participation in the trial according to the investigator,
- •Patient who participate in another clinical trial.
Outcomes
Primary Outcomes
Percentage of patients having a clinical healing of their anoperineal fistulas in Crohn disease
Time Frame: 12 months after seton drain removal
Secondary Outcomes
- Change in fistula activity assessed by magnetic resonance imaging (MRI)(6, 12 and 24 months after seton drain removal)
- Change in Crohn disease activity assessed by Crohn's Disease Activity Index (CDAI) and Perianal Disease Activity Index (PDAI)(3, 6, 12 and 24 months after seton drain removal)
- Change in anal continence assessed by Wexner and Vaizey scores(12 and 24 months after seton drain removal)
- Crohn's Disease Endoscopic Index of Severity (CDEIS)(12 months after seton drain removal)
- Change in discomfort and impact assessed by the patient using a visual analog scale (VAS)(3, 6, 12 and 24 months after seton drain removal)
- Proportion of patients having more than half of their fistulas healed(3, 6, 12 and 24 months after seton drain removal)
- Change in patients' quality of life, assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ)(12 and 24 months after seton drain removal)
Study Sites (15)
Loading locations...
Similar Trials
Completed
Phase 3
Safety and Efficacy of Adalimumab in Patients Who Showed an Unsatisfactory Response to EtanerceptPlaque PsoriasisNCT00927069Innovaderm Research Inc.85
Completed
Phase 2
ADalimumab in Persistent Early Oligoarthrits Study (ADEOS)OligoarthritisNCT04154852University of Leeds22
Completed
Phase 3
Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative ColitisUlcerative ColitisNCT00385736Abbott576
Completed
Phase 3
Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)Generalized Pustular Psoriasis (GPP)AdalimumabJapaneseNCT02533375AbbVie10
Completed
Phase 2
A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's DiseaseCrohn's DiseaseNCT00445939Abbott90